---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-454423"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2026-11-10T12:10:18+00:00"
generated_at: "2026-11-10T12:15:05.014098+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock to sell PRV to BioNTech for $205M; Q3 EPS loss $0.81, first ISEMBYLD revenue $0.6M

## Summary
- Definitive PRV asset purchase agreement signed Nov 9, 2026 with BioNTech US Inc.; $205M in cash payable at closing, subject to HSR waiting-period expiration.
- Q3 2026 net loss $107.2M ($0.81 per share) vs $102.2M ($0.90 per share) a year earlier; net product revenue of $0.6M from ISEMBYLD after Sept 11 FDA approval.
- Cash, cash equivalents and marketable securities of $413.6M at Sept 30, 2026; R&D $54.1M, SG&A $52.5M, stock-based compensation $17.9M.
- EMA validated the apitegromab MAA resubmission in October 2026, with CHMP opinion expected H1 2027; Japanese JNDA accepted under priority review (~9-month cycle).
- SRK-439 Phase 1 topline data expected by year-end 2026; FSHD FORGE Phase 2 enrolling ~60 patients; FDA granted Fast Track and Orphan Drug designations in September 2026.

## SEC filing metadata
- accession: 0001193125-26-454423
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2026-11-10T12:10:18+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000119312526454423/0001193125-26-454423-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000119312526454423/srrk-20261110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-454423
- JSON: https://secwatch.observer/filing/0001193125-26-454423.json
- Plain text: https://secwatch.observer/filing/0001193125-26-454423.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.